Guiding clinical decisions on abdominal obesity and cardiometabolic risk

Clinical Cornerstone

Volumn 9, Issue 4, 2009, Pages 43-54

  Nesto, Richard W ^a   Nelinson, Donald S ^b   Pagotto, Uberto ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b The Diabetes Consortium Inc Mountain Lakes   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ATORVASTATIN; CANNABINOID RECEPTOR ANTAGONIST; PLACEBO; PRAVASTATIN; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

ABDOMINAL OBESITY; ADIPOSE TISSUE; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIZZINESS; DRUG MEGADOSE; ENDOCRINE GLAND; ENDOTHELIUM; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; INSULIN SENSITIVITY; LIFESPAN; LIFESTYLE MODIFICATION; METABOLIC DISORDER; METABOLIC SYNDROME X; MOOD DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK REDUCTION; SUICIDAL BEHAVIOR; WEIGHT REDUCTION;

ADIPOSITY; APPETITE DEPRESSANTS; BARIATRIC SURGERY; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HEALTH BEHAVIOR; HUMANS; LIFE STYLE; METABOLIC SYNDROME X; OBESITY, ABDOMINAL; RISK FACTORS; WAIST CIRCUMFERENCE; WEIGHT LOSS;

EID: 70349303461     PISSN: 10983597     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1098-3597(09)80004-5     Document Type: Article

References (55)

1. Weight-control Information Network, an information service of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Statistics related to overweight and obesity. http://www.win.niddk.nih.gov/STATISTICS/ Accessed May 5, 2009
2. National Center for Health Statistics. Health, United States, 2008 with Special Feature on the Health of Young Adults. Hyattsville, Md (2009). http://www.cdc.gov/nchs/data/hus/hus08.pdf Accessed April 3, 2009
3. World Health Organization. Global Health Atlas. Data query: World health statistics, health status indicators. Adult obesity prevalence, female and male, 1998 to 2004. http://www.who.int/globalatlas/dataQuery/ Accessed May 13, 2009
4. International Diabetes Federation. Diabetes Atlas. 3rd ed. (2007), International Diabetes Federation, Brussels, Belgium. http://www.eatlas.idf.org/index1397.html Accessed May 5, 2009
5. Colditz G.A., Willett W.C., Rotnitzky A., and Manson J.E. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med. 122 (1995) 481-486
6. Thom T., Haase N., Rosamond W., et al., the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2006 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Committee [published correction appears in Circulation. 2006;113:e696]. Circulation 113 (2006) e85-e151
7. Dagenais G.R., Yi Q., Mann J.F., et al. Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. Am Heart J. 149 (2005) 54-60
8. Rexrode K.M., Carey V.J., Hennekens C.H., et al. Abdominal adiposity and coronary heart disease in women. JAMA 280 (1998) 1843-1848
9. Alexander C.M., Landsman P.B., Teutsch S.M., Haffner S.M., and the Third National Health and Nutrition Examination Survey (NHANES III) and National Cholesterol Education Program (NCEP). NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and older. Diabetes 52 (2003) 1210-1214
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with sim-vastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360 (2002) 7-22
11. Haffner S.M., Lehto S., Rönnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 339 (1998) 229-234
12. Grundy S.M., Cleeman J.I., Daniels S.R., et al., the American Heart Association and National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement [published correction appears in Circulation. 2005;112:e297, e298]. Circulation 112 (2005) 2735-2752
13. Després J.P., and Lemieux I. Abdominal obesity and metabolic syndrome. Nature 444 (2006) 881-887
14. Kahn R., Buse J., Ferrannini E., Stern M., and the American Diabetes Association and European Association for the Study of Diabetes. The metabolic syndrome: Time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
15. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
16. Chung E.H., Curran P.J., Sivasankaran S., et al. Prevalence of metabolic syndrome in patients ≤45 years of age with acute myocardial infarction having percutaneous coronary intervention. Am J Cardiol 100 (2007) 1052-1055
17. Yan L.L., Daviglus M.L., Liu K., et al. Midlife body mass index and hospitalization and mortality in older age. JAMA 295 (2006) 190-198
18. Calle E.E., Thun M.J., Petrelli J.M., et al. Body-mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med. 341 (1999) 1097-1105
19. Yusuf S., Hawken S., Ounpuu S., et al., the INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 364 (2004) 937-952
20. Klein S., Allison D.B., Heymsfield S.B., et al., the Association for Weight Management and Obesity Prevention, NAASO, Obesity Society, American Society for Nutrition, American Diabetes Association. Waist circumference and cardiometabolic risk. A consensus statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, The Obesity Society; the American Society for Nutrition; and the American Diabetes Association. Diabetes Care 30 (2007) 1647-1652
21. Nicklas B.J., Cesari M., Penninx B.W., et al. Abdominal obesity is an independent risk factor for chronic heart failure in older people. J Am Geriatr Soc. 54 (2006) 413-420
22. Rana J.S., Mittleman M.A., Ho K.K., and Cutlip D.E. Obesity and clinical restenosis after coronary stent placement. Am Heart J. 150 (2005) 821-826
23. Shivalkar B., Van de Heyning C., Kerremans M., et al. Obstructive sleep apnea syndrome: More insights on structural and functional cardiac alterations, and the effects of treatment with continuous positive airway pressure. J Am Coll Cardiol 47 (2006) 1433-1439
24. Chinali M., de Simone G., Roman M.J., et al. Impact of obesity on cardiac geometry and function in a population of adolescents: The Strong Heart Study. J Am Coll Cardiol 47 (2006) 2267-2273
25. LaRosa J.C., Grundy S.M., Waters D.D., et al., the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 352 (2005) 1425-1435
26. Deedwania P., Barter P., Carmena R., et al., the Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the Treating to New Targets study. Lancet 368 (2006) 919-928
27. Ridker P.M., Cannon C.P., Morrow D., et al., the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 352 (2005) 20-28
28. Ray K.K., Cannon C.P., Cairns R., et al., the PROVE IT-TIMI 22 Investigators. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol. 46 (2005) 1417-1424
29. Gregg E.W., Cheng Y.J., Cadwell B.L., et al. Secular trends in cardiovascular disease risk factors according to body mass index in US adults [publication correction appears in JAMA. 2005;294:182]. JAMA. 293 (2005) 1868-1874
30. Kershaw E.E., and Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 89 (2004) 2548-2556
31. Lyon C.J., Law R.E., and Hsueh W.A. Minireview: Adiposity, inflammation, and atherogenesis. Endocrinology. 144 (2003) 2195-2200
32. Henrichot E., Juge-Aubry C.E., Pernin A., et al. Production of chemokines by perivascular adipose tissue: A role in the pathogenesis of atherosclerosis?. Arterioscler Thromb Vasc Biol. 25 (2005) 2594-2599
33. Wellen K.E., and Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. J Clin Invest. 112 (2003) 1785-1788
34. Greenberg A.S., and Obin M.S. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr. 83 (2006) 461S-465S
35. Caballero A.E. Endothelial dysfunction in obesity and insulin resistance: A road to diabetes and heart disease. Obes Res. 11 (2003) 1278-1289
36. Goldstein B.J., and Scalia R. Adiponectin: A novel adipokine linking adipocytes and vascular function. J Clin Endocrinol Metab. 89 (2004) 2563-2568
37. Tahara N., Kai H., Yamagishi S., et al. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol. 49 (2007) 1533-1539
38. McGill Jr. M.C., McMahan C.A., Herderick E.E., et al., the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Obesity accelerates the progression of coronary atherosclerosis in young men. Circulation. 105 (2002) 2712-2718
39. Juonala M., Järvisalo M.J., Mäki-Torkko N., et al. Risk factors identified in childhood and decreased carotid artery elasticity in adulthood: The Cardiovascular Risk in Young Finns Study. Circulation. 112 (2005) 1486-1493
40. Prior J.O., Quiñones M.J., Hernandez-Pampaloni M., et al. Coronary circulatory dysfunction in insulin resistance, impaired glucose tolerance, and type 2 diabetes mellitus. Circulation. 111 (2005) 2291-2298
41. Rutter M.K., Parise H., Benjamin E.J., et al. Impact of glucose intolerance and insulin resistance on cardiac structure and function: Sex-related differences in the Framing-ham Heart Study. Circulation. 107 (2003) 448-454
42. McGavock J.M., Lingvay I., Zib I., et al. Cardiac steatosis in diabetes mellitus: A 1H-magnetic resonance spectroscopy study. Circulation. 116 (2007) 1170-1175
43. Dunbar R.L., and Rader D.J. Slaying the metabolic syndrome. Are we battling the Hydra or the Chimera?. Minerva Endocrinol. 29 (2004) 89-111
44. National Heart, Lung, and Blood Institute and North American Association for the Study of Obesity (NAASO). The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults (2000). http://www.nhlbi.nih.gov/guidelines/obesity/practgde.htm NIH publication 00-4084. Accessed May 8, 2009
45. Li Z., Maglione M., Tu W., et al. Meta-analysis: Pharmacolog-ic treatment of obesity. Ann Intern Med. 142 (2005) 532-546
46. Pagotto U., Marsicano G., Cota D., et al. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev. 27 (2006) 73-100
47. Fong T.M., Guan X.M., Marsh D.J., et al. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents. J Pharmacol Exp Ther. 321 (2007) 1013-1022
48. Van Gaal L.F., Rissanen A.M., Scheen A.J., et al., the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients. 1-Year experience from the RIO-Europe study [published correction appears in Lancet. 2005;366:370]. Lancet. 365 (2005) 1389-1397
49. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., et al., the RIO-North America Study Group. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardio-metabolic risk factors in overweight or obese patients: RIO-North America. A randomized controlled trial [published correction appears in JAMA. 2006;295:1252]. JAMA. 295 (2006) 761-775
50. Després J.P., Golay A., Sjöström L., and the Rimonabant in Obesity-Lipids Study Group. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipi-demia. N Engl J Med. 353 (2005) 2121-2134
51. Scheen A.J., Finer N., Hollander P., et al., the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: A randomised controlled study [published correction appears in Lancet. 2006;368:1650]. Lancet. 368 (2006) 1660-1672
52. Rosenstock J., Iranmanesh A., and Hollander P. Improved glycemic control with weight loss plus beneficial effects on atherogenic dyslipidemia with rimonabant in drug-naive type 2 diabetes: The SERENADE Trial. Presented at: 67th Annual Scientific Sessions of the American Diabetes Association. Chicago, Ill (June 22-26, 2007)
53. US Food and Drug Administration. Presentations to the Endocrinologic and Metabolic Drugs Advisory Committee (June 13, 2007). www.fda.gov/OHRMS/DOCKETS/AC/cder07.htm#EndocrinologicMetabolic Accessed May 8, 2009
54. McMahon M.M., Sarr M.G., Clark M.M., et al. Clinical management after bariatric surgery: Value of a multidisci-plinary approach. Mayo Clin Proc. 81 (2006) S34-S45
55. Adams T.D., Gress R.E., Smith S.C., et al. Long-term mortality after gastric bypass surgery. N Engl J Med. 357 (2007) 753-761